Galderma set to launch Nuvo's Pliaglis in EU
This article was originally published in Scrip
Executive Summary
Dermatology company Galderma has received its first three EU marketing licences for its topical pain drug Pliaglis (tetracaine and lidocaine), with plans to launch in the first half of 2013.